Literature DB >> 18219690

Appetite stimulants use in cystic fibrosis.

Samya Z Nasr1, Donna Drury.   

Abstract

Cystic fibrosis (CF) is an autosomal recessive disease. It affects multiple body organs. The lungs and pancreas are the most affected which results in progressive lung damage and pancreatic insufficiency. Due to the disease process, CF patients require significantly higher caloric intake than recommended for other individuals. The nutritional goal for CF patients is to achieve normal growth and development and, once genetic potential is reached, to maintain good nutritional status throughout life. Evidence has shown that lung function is closely associated with nutritional status in CF and that nutritional status is an independent predictor of survival. Most CF patients are on a high calorie diet to help achieve normal growth and development and maintain good lung function. Inadequate caloric intake in CF can lead to malnutrition. Malnutrition in CF requires careful, multidisciplinary history taking, physical exam, and overall patient/family assessment. Only by determining the actual cause of the malnutrition can appropriate and safe therapies be used to treat it. Appetite stimulants, although efficacious in treating malnutrition in CF, should only be prescribed if decreased food intake secondary to inadequate appetite is the principal cause of the malnutrition and all other contributing factors have been assessed, ruled-out or treated. In this review, we attempted to summarize the use of several appetite stimulants used in CF and other diseases to improve appetite and maximize caloric intake. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18219690     DOI: 10.1002/ppul.20766

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  6 in total

1.  Nutritional outcomes following gastrostomy in children with cystic fibrosis.

Authors:  Gia M Bradley; Kathryn A Carson; Amanda R Leonard; Peter J Mogayzel; Maria Oliva-Hemker
Journal:  Pediatr Pulmonol       Date:  2012-02-01

2.  Altered de novo lipogenesis contributes to low adipose stores in cystic fibrosis mice.

Authors:  Ilya Bederman; Aura Perez; Leigh Henderson; Joshua A Freedman; James Poleman; Dana Guentert; Nicholas Ruhrkraut; Mitchell L Drumm
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-06-07       Impact factor: 4.052

Review 3.  Appetite stimulants for people with cystic fibrosis.

Authors:  Diane McTavish; Judith Thornton
Journal:  Cochrane Database Syst Rev       Date:  2022-09-23

4.  Oxandrolone Improves Height Velocity and BMI in Patients with Cystic Fibrosis.

Authors:  Todd Varness; Erin E Seffrood; Ellen L Connor; Michael J Rock; David B Allen
Journal:  Int J Pediatr Endocrinol       Date:  2010-01-24

5.  Growth failure and treatment in cystic fibrosis.

Authors:  Trang N Le; Abeer Anabtawi; Melissa S Putman; Vin Tangpricha; Michael S Stalvey
Journal:  J Cyst Fibros       Date:  2019-10       Impact factor: 5.482

Review 6.  Inactivation of FOXA2 by Respiratory Bacterial Pathogens and Dysregulation of Pulmonary Mucus Homeostasis.

Authors:  Woosuk Choi; Shawn Choe; Gee W Lau
Journal:  Front Immunol       Date:  2020-03-25       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.